Bavarian Nordic's MVA-BN patent stands in European validity challenge
The patent was granted in December 2005 and after the nine month opposition period in which any third party can file an opposition against any patent granted in a European jurisdiction, seven companies opposed the patent. The opposition proceeding has been pending at the European Patent Office for several years.
After an oral hearing in the first instance the Opposition Division today rendered its decision to uphold the patent with certain amended claims.
Bavarian Nordic's President & CEO, Anders Hedegaard commented: "We are very pleased with the decision by the first instance to uphold our core patent, thus confirming its uniqueness. We have substantially invested our resources to develop our MVA BN® technology and our efforts have led to the creation of valuable intellectual property, which we successfully have defended today."
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.